<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947348</url>
  </required_header>
  <id_info>
    <org_study_id>A3-912-OA-801</org_study_id>
    <nct_id>NCT01947348</nct_id>
  </id_info>
  <brief_title>Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis</brief_title>
  <official_title>Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Regenerative and Cellular Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Regenerative and Cellular Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To purpose of this study is to determine if treatment with SVF (Stromal Vascular Fraction)&#xD;
      has an effect on pain and inflammation associated with Osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective non-randomized, clinical study of 30 patients to determine safety and&#xD;
      treatment potential of A3(Adult Autologous Adipose) SVF for the pain and inflammation&#xD;
      associated with Osteoarthritis.&#xD;
&#xD;
      Patients will be treated for Osteoarthritis due to degeneration or chronic injury. They will&#xD;
      be given autologous SVF extract derived by the A3 method mixed with activated platelets from&#xD;
      a PRP(platelet rich plasma) preparation as direct injections to the effected joints. Outcomes&#xD;
      will be tracked with WOMAC (Western Ontario and McMaster Universities Arthritis Index),&#xD;
      AUSCAN(Australian Hand Osteoarthritis Index) scores, and a general blood panel in order to&#xD;
      evaluate systemic effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain and Inflammation - WOMAC scores, comprehensive inflammation blood panel</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain and Mobility Assessment</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>treatment with A3 SVF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients that have been treated. The control patients that have not been treated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>treatment with A3 SVF</intervention_name>
    <description>Treatment interarticular and IV with A3 SVF</description>
    <arm_group_label>treatment with A3 SVF</arm_group_label>
    <other_name>A3 SVF, Cell Extracts, Adipose Derived Stem Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with indication of Osteoarthritis. Can be from degeneration or chronic&#xD;
             injury.&#xD;
&#xD;
          -  Patients range from 15-90 years of age.&#xD;
&#xD;
          -  Female patients not pregnant or lactating.&#xD;
&#xD;
          -  Patients with a history of or current corticosteroid therapy will only be eligible if&#xD;
             use is suspended from 1 month prior to cell therapy.&#xD;
&#xD;
          -  Patients must be able to comply with treatment plan, laboratory tests and periodic&#xD;
             interviews.&#xD;
&#xD;
          -  Patients with adequate renal function, creatinine ≤ 1.5 mg/dl.&#xD;
&#xD;
          -  Patients with adequate blood coagulation activity, PT(INR) &lt; 1.5, APTT &lt;1.5×control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cancer within 5 years prior to screening, except for cutaneous basal cell&#xD;
             or squamous cell cancer resolved by excision.&#xD;
&#xD;
          -  Signs and symptoms of clinically significant cardiac disease.&#xD;
&#xD;
          -  Diagnosis of a transient ischemic attack in the 6 months prior to screening,&#xD;
&#xD;
          -  Known allergy to anesthetic or any other components of study.&#xD;
&#xD;
          -  Patients infected with hepatitis B, C or HIV.&#xD;
&#xD;
          -  Patients with Body Mass Index (BMI) &gt; 39kg/m2 .&#xD;
&#xD;
          -  Any other cardiovascular illness that in the opinion of the investigator would render&#xD;
             a patient unsuitable to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Krutchkoff</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Regenerative and Cellular Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Huh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Huh, MD</last_name>
    <phone>213 384 1717</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Dr John Huh</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Huh, MD</last_name>
      <phone>213-384-1717</phone>
      <email>drjhuh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>John Huh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cellmedicinesociety.org/</url>
    <description>IRB</description>
  </link>
  <link>
    <url>http://www.auscan.org/womac/index.htm</url>
    <description>Info regarding outcome measures</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>March 15, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <last_update_submitted>September 2, 2014</last_update_submitted>
  <last_update_submitted_qc>September 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Regenerative and Cellular Medicine</investigator_affiliation>
    <investigator_full_name>barbara krutchkoff</investigator_full_name>
    <investigator_title>Dr John Huh, Los Angeles</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

